Convenient, consistent and credible in gluten challenges throughout your program.
Novoviah develops customised ultrasensitive “Novoleukin” test kits to measure antigen-specific T cells during clinical trials.
Our Novoleukin T-cell testing system detects T cells when others don’t.
After 20+ years research, the first indication demonstrated for the Novoleukin Test System was is in Celiac Disease.
Novoviah’s aspiration is to impact awide range of immune disease, therapies and vaccines.
Novoviah works closely with your research and development team anywhere in the world to create a Novoleukin Test System customised to your needs and your antigens.
We make monitoring for antigen-specific T cells easy and sensitive for a clinical trial, by leveraging exceptional quality whole blood incubation with antigen at the trial site with standardised high-performance immunoassay at the central lab.
The key, proprietary intellectual property is the Novoleukin test system, a “whole blood antigen-stimulated cytokine release assay” which is substantially more sensitive than conventional fresh PBMC-based ELISpot assay (e.g. for detection of gluten-reactive CD4+ T cells in celiac disease).
Novoviah has extensive experience of the Novoleukin Test System in Celiac Disease. The Novoleukin-C test for gluten-specific T cells associated with celiac disease is reliable even in patients who have not completed a gluten food challenge. This is a landmark achievement in the field.
Novoviah’s aspiration is to have a Novoleukin Test System available for a wide range of antigens relevant to immune disease, therapies and vaccines, and to explore their clinical utility as diagnostics or monitoring tools.
A “whole blood antigen-stimulated cytokine release assay” which is substantially more sensitive.
The protocol for blood collection and processing is simple and reproducible, to enable easy rollout across multiple sites.
The Novoleukin Test System comprises three key elements: test kit and protocol, specific stimulation of cytokine release and central Lab Performing ultrasensitive cytokine assay.
"Novoviah’s Founders are passionate about simple high performance T cell testing as diagnostic and monitoring tools accelerating pharmaceutical development, providing a new class of diagnostics, and allowing personalised treatment.
Novoviah’s Novoleukin Test System has widespread application measuring rare antigen-specific T cells in autoimmunity, infectious diseases, cancer, vaccine and immunotherapy development, or as a powerful new clinical research tool.
Novoviah has been built on our Founders’ over 20 years’ experience in discovery and commercialization of diagnostics and therapeutics for celiac disease and other immune diseases. Our Founders aim to bring simplicity and highest quality outcomes to support pharmas and biotech in preclinical and early clinical development of immunotherapy."
Explore the latest insights and advancements in T cell testing with Novoviah. Our blog, publications, and news articles offer a comprehensive look into our T cell testing platform for clinical trials and beyond. Stay informed with Novoviah's innovative solutions in biotechnology.
Novoviah is dedicated to pioneering sensitive clinical tests for antigen-specific T cells, supporting clinical trials for drug developers and researchers. Established in 2020, Novoviah specialised in developing a cutting-edge testing platform for clinical trials and aspires to expand its usage into healthcare settings in the future. With a focus on enhancing pharmaceutical programs, Novoviah is committed to developing customised and highly precise blood tests for a variety of medical conditions associated with antigen-specific T cells.
Novoviah Pharmaceuticals Pty Ltd | Novoviah, NovoGluten, NovoLeukin and NovoFind are all registered trademarks. | Website maintained & hosted by Web Set Go